A Controlled Trial of Aspirin in Childhood Glomerular Disorders

Carl W. Trygstad; Nils U. Bang; Robert O. Heldenreich; Barbara M. Csiscko; Bruce Rodda

doi:10.1055/s-0038-1649097

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1973; 30(01): 012-017
DOI: 10.1055/s-0038-1649097

Original Article

Schattauer GmbH

A Controlled Trial of Aspirin in Childhood Glomerular Disorders

Autor*innen

Carl W. Trygstad^*

¹Department of Pediatrics and Medicine, Indiana University-Purdue University Indianapolis, School of Medicine and Lilly Laboratory for Clinical Research
Nils U. Bang

¹Department of Pediatrics and Medicine, Indiana University-Purdue University Indianapolis, School of Medicine and Lilly Laboratory for Clinical Research
Robert O. Heldenreich

¹Department of Pediatrics and Medicine, Indiana University-Purdue University Indianapolis, School of Medicine and Lilly Laboratory for Clinical Research
Barbara M. Csiscko

¹Department of Pediatrics and Medicine, Indiana University-Purdue University Indianapolis, School of Medicine and Lilly Laboratory for Clinical Research
Bruce Rodda

¹Department of Pediatrics and Medicine, Indiana University-Purdue University Indianapolis, School of Medicine and Lilly Laboratory for Clinical Research

Abstract

Summary

A controlled, prospective, double-blind study of the effect of aspirin on the clinical course and renal function of 36 children with proliferative glomerulonephritis or the nephrotic syndrome was undertaken. Despite unequivocal evidence of suppression of platelet aggregation with aspirin treatment, there were no statistically significant changes in the clinical course or any of the laboratory parameters denoting activity of the chronic glomerular renal disorder. It would appear, therefore, that additional factors besides local platelet aggregation must be involved in the perpetuation of chronic childhood renal disease.

Volltext

Referenzen

References
1 Abramowicz M, Barnett H. L, Edelman Jr. C. M, Grtjfer I, Kabazashi O, Arneil G. C, Barron B. A, Gordillo P. G, Hallman N, and Tiddens H. A. 1970; Controlled trial of azathioprine in children with nephrotic syndrome. Lancet 1: 959.
2 Bang N. U, Trygstad C. W, Schroeder J. E, Heidenreich R. O, and Csiscko B. M. 1973; Enhanced platelet function in glomerular renal disease. Journal of Laboratory and Clinical Medicine 81: 651.
3 Barratt T. M, and Soothill J. F. 1970; Controlled trial of cyclophosphamide in steroid sensitive relapsing nephrotic syndrome of childhood. Lancet 2: 479.
4 Cade J. R, Dequesada A. M, Shires D. L, Levin D. M, Hackett R. L, Spooner G. R, Schein E. M, Pickering M. J, and Holcomb A. 1971; The effect of long term high dose heparin treatment on the course of chronic proliferative glomerulonephritis. Nephron 8: 67.
5 Duffy J.L, Cinque T, Grisham E, and Chung J. J. 1970; Intraglomerular fibrin, platelet aggregation and subendothelial deposits in lipoid nephrosis. Journal of Clinical Investigation 49: 251.
6 Henson P. M, and Cochrane C. G. 1971; Acute immune complex disease in rabbits. Journal of Experimental Medicine 133: 554.
7 Herdman R. L, Edson J. R, Pickering R. J, Fish A. J, Marker S, and Good R. A. 1970; Anticoagulation in renal disease in children. American Journal of Diseases of Children 119: 27.
8 Kallen R. J, and Lewis E. J. 1973; “Immunosuppressive” treatment of “chronic glomerulonephritis.”. Journal of Pediatrics 82: 335.
9 Kincaid-Smith P. 1972; Coagulation and renal disease. Kidney International 2: 183.
10 Kincaid-Smith P, Saker B. M, and Fairley K. F. 1968; Anticoagulants in “irreversible” acute renal failure. Lancet 2: 1360.
11 Stiehm E. R, and Trygstad C. W. 1969; Split products of fibrin in human renal disease. American Journal of Medicine 46: 786.
12 Trygstad C. W, and Anand S. K. 1972; Glomerulonephritis in childhood. Current Problems in Pediatrics 2: 3.
13 Vassalli P, and McCluskey R. T. 1964; The pathogenic role of the coagulation process in rabbit masugi nephritis. American Journal of Pathology 45: 653.